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Abstract
Background
We report a feasibility study based on our large-scale experience with mycophenolate mofetil (MMF) dose adjustment based on
mycophenolic acid (MPA) inter-dose area under the curve (AUC) in renal transplant patients.
Methods
Between 2005 and 2010, 13930 requests for 7090 different patients (outside any clinical trial) were posted by more than 30 different
transplantation centres on a free, secured website for MMF dose recommendations using 3 plasma concentrations and Bayesian
estimation.
Results
This retrospective study showed that: (i) according to a consensually recommended 30 60 mg.h/L target, dose-adjustment was needed–
for about 35  of the patients, 25  being underexposed with the highest proportion observed in the first weeks after transplantation;% %
(ii) when dose adjustment had been previously proposed, the subsequent AUC was significantly more often in the recommended
range if the dose was applied than not, at all post-transplantation periods (72 80  vs. 43 54 ); (iv) and the interindividual AUC– % – %
variability in the respected-dose  group was systematically lower than that in the not respected-dose  group (depending on the“ ” “ ”
post-transplantation periods, CV   31 to 41  versus 49 to 70 , respectively). Further analysis suggested that MPA AUC should% = % %
best be monitored at least every two weeks during the first month, every 1 3 months between months 1 and 12, while in the stable–
phase, the odds to be still in the 30 60 range on the following visit was still 75.0  up to one year after the previous dose adjustment.– %
Conclusion
This study showed that the monitoring of MMF on the basis of AUC measurements is a clinically feasible approach, apparently
acceptable by the patients, the nurses and the physicians, owing to its large use in routine clinics.
MESH Keywords Area Under Curve ; Bayes Theorem ; Drug Dosage Calculations ; Drug Monitoring ; methods ; Humans ; Immunosuppressive Agents ; administration &
dosage ; pharmacokinetics ; Kidney Transplantation ; Mycophenolic Acid ; administration & dosage ; analogs & derivatives ; pharmacokinetics ; Retrospective Studies
Author Keywords Mycophenolate mofetil ; Therapeutic drug monitoring ; Pharmacokinetic modelling ; Bayesian estimation
Introduction
There is still ongoing debate regarding the added value of therapeutic drug monitoring (TDM) for mycophenolate mofetil (MMF)
given as an immunosuppressive drug to prevent acute rejection following solid organ transplantation. As mentioned in the review articles
on MMF TDM published over the last ten years ( ), the general routine use of MMF TDM cannot be formally recommended on the1 –11 
basis of the available evidence. This is mainly due to the conflicting results of randomized studies that examined the clinical benefit of
MMF TDM ( , ).12 13 
However, it is not questionable that: (i) MMF exhibits large interindividual pharmacokinetic variability due to numerous factors, such
as liver and renal functions, serum albumin levels or associated drugs; (ii) for a daily dose of 2 g, the inter-dose area-under-the curve
(AUC) of mycophenolic acid (MPA) can vary 10-fold between patients; and (iii) that MPA AUC is better correlated with patients0-12h ’
outcome than any single concentration-time point, as shown at least by retrospective exposure-outcome studies. Moreover a
time-dependent increase in dose-standardized MPA exposure as measured by the inter-dose area-under-the-curve (AUC) has been reported
( 40  on average over the first 3 months posttransplantation). In this context, consensus conferences converged to the point that an MPA+ %
AUC between 30 and 60 mg.h/L should be targeted, at least over the first six months post-kidney or heart transplantation and when0-12h 
MMF is used in combination with cyclosporine and steroids. Interestingly, the last consensus report advised to prefer drug dosing based on
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MPA inter-dose AUC when obtained using limited sampling strategies (LSS) rather than based on single MPA (trough) concentrations (1 
).
Nevertheless, one of the arguments frequently put forward against MMF monitoring based on AUC is that it would not be feasible,
owing to clinical constraints. In this context, based on original pharmacokinetic models built from large populations of transplanted
patients enrolled in pharmacokinetic studies promoted and coordinated by the Limoges University Hospital, other academic institutions or
by pharmaceutical companies, we previously developed Bayesian estimators to estimate MPA AUC using sparse individual data,0-12h 
hence the dose to reach an AUC target value for each patient ( ). In April 2005, we launched an expert system for14 –16 
ImmunoSuppressants Bayesian dose Adjustment (ISBA) and made it accessible to all transplantation centres worldwide through a free
website ( ). The objective of this service is to offer dose adjustment of MMF by providing: individual patient s exposure to the drug17 ’
(inter-dose area under the curve, i.e., AUC for b.i.d. and AUC for t.i.d. dosing) estimated using Maximum a Posteriori Bayesian0-12h 0-8h 
Estimators (MAP-BEs) on the basis of three blood samples collected in the first three hours following drug intake; the modelled
concentration-time curve; and one or a range of recommended dose(s) to reach the therapeutic target. MAP-BEs developed and validated
in kidney transplant recipients receiving MMF in association with cyclosporine ( ) or tacrolimus are, among others, available14 –16 
through this website.
To address the concern of MMF dose adjustment feasibility, the objectives of this retrospective analysis of the routine requests for
MMF dose adjustment in adult renal transplant patients posted on the ISBA website over the first 5 years of activity, were: (i) to study the
MMF doses prescribed; (ii) to describe the distribution of the exposure to MPA after MMF dosing, hence the percentage of patients in
whom a dose change was necessary to reach the target range  of MPA AUC ; (iii) to evaluate whether the Bayesian estimators used‘ ’ 0-12h 
and doses recommended were actually able to increase the probability of the next MPA AUC to be in this target range; (iv) to evaluate0-12h 
the extent of intraindividual variability in the AUC; (v) and to propose recommendations about how frequent MMF dose adjustments
should be to maintain MPA AUC within this range.0-12h 
Material and methods
The PK models and Bayesian estimators used by the ISBA expert system for MMF dose adjustment were previously described (14 –16
). Briefly, concentration data obtained in or stable transplant patients can be fitted using: a single-compartment model with ade novo 
double gamma input allowing good fitting of the double-peak concentration time curves (most frequently observed in the first months–
after transplantation); or a 2-compartment model with a single gamma input for the absorption phase (curves with a single peak). Several
Bayesian Estimators allowing the determination of individual PK parameters and the calculation of the AUC value were developed, using
either the Iterative Two-Stage Bayesian approach ( , ) or non-linear mixed effects modelling (The program Wings for NONMEM18 19 
version 405 ; Globomax, Hanover, USA). Each of them was developed from a specific database characterizedhttp://wfn.sourceforge.net/ 
by the type of graft, the post-transplantation period, the associated immunosuppressive regimen and the analytical method used for MPA
determination. For each of them, either external or internal validation (i.e., in an independent group of patients or using the data-splitting
approach, respectively) was performed before any clinical use. These pharmacokinetic tools have been developed from patients given
Cellcept  and are not suited for other formulations of mycophenolate mofetil or other forms of mycophenolate. Several of these tools have®
also been used in TDM-validation or controlled-concentration trials ( , ). The Bayesian estimators used on the website for a dose13 20 
adjustment of MMF in solid transplantation are all based on the same limited sampling strategy (LSS), i.e. 20min, 60min and 180min after
the morning dose. Respecting this LSS is mandatory but, according to the flexibility of any Bayesian estimator and based on the results of
validation data of these tools, acceptable ranges around these theoretical sampling times have been defined. Precisely, on the form to fill in
on the website, centres are informed that samples must be taken at 20 10min, 60 15min and 180 30min.± ± ±
All the AUC results and dose adjustments calculated using these tools are validated by a pharmacologist before reporting the results on
the ISBA website. This means checking the estimated profile versus the measured concentrations and the current AUC estimate with
regards to previous ones for the same patient (if any). In case of unlikely MPA concentrations, bad fitting or discrepancy with previous
results, the pharmacologists in charge of the expert system can ask the physician or the clinical chemist for data confirmation or correction,
or may model the data again using a close but different Bayesian estimator. For instance, MPA PK maturation  over post-transplantation“ ”
time is variable between patients, some reaching a stable clearance (and AUC) more rapidly than others, so that as soon as M3 or M4 in
some patients, the Bayesian estimators aimed at the stable period (> 1 year) can be more appropriate than those intended for the M3-M6
period. For the last couple of years, this process has been automated by modeling each profile with 3 5 different models (i.e., for adjacent–
periods, using one or two peaks), and using the Bayesian Information Criteri (BIC) or Schwarz s criteria to select the model that best’
explains each individual data with a minimum of PK parameters (in order to prevent overfitting) ( ). For each patient, the result21 
corresponding to the lowest AIC value is proposed first hand, and has to be validated by a trained pharmacologist before reporting.
The requests for routine MMF dose adjustment concerning adult renal transplant recipients not enrolled in any kind of
concentration-controlled clinical trial and posted on the ISBA website ( ) within a 5-year period (i.e., from April 2005 to April 2010)17 
were retrospectively studied. For each request, the following information was obtained: time elapsed since transplantation, MMF daily
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dose, immunosuppressive co-treatment, date of the previous dose adjustment (if any), calculated AUC value at the different visits (if any),
doses proposed to reach AUC values of 30 to 60 mg.h/L.(or AUC of 20 to 40 mg.h/L when MMF is given three times daily). In the0-8h 
present study, only the requests where the MPA measurements were performed using either an HPLC technique (UV or MS detection) or
the enzyme inhibition assay were considered.
Using this database, we tried to answer the following questions:
Depending on the associated CNI and the time elapsed since transplantation, what are the MMF doses prescribed to renal transplant
patients, before any dose adjustment?
For this study, only requests corresponding to the first request posted on our website for each patient was considered.
What percentage of patients actually needed MMF dose adjustment to reach the 30 60 mg.h/L range?–
The percentage of calculated AUCs in the 30 60 mg.h/L range was calculated in subgroups defined by the nature of the associated–
CNI and the time elapsed since transplantation. Accordingly, the percentages of dose increments or dose decreases proposed were also
determined.
What is the efficacy of MMF dose adjustment based on Bayesian AUC estimation?
The efficacy of the proposed dose adjustments was evaluated using data from the patients with multiple AUC measurements posted on
the website, considering separately those in whom the given dose was still in the dose range proposed at the previous request (i.e., doses to
reach AUC values of 30 and 60 mg.h/L, respectively) and those receiving a dose outside this previously proposed dose range. The
percentages of patients with current AUC within the therapeutic range were calculated and statistically compared using chi-square tests,
taking into account both the post-transplantation period in which each previous  dose recommendation was made and time space between“ ”
the previous dose recommendation and the current request.
What is the extent of AUC intra-individual variability, and is the dose-exposure relationship linear in the stable period?
We studied the following situations:
If a patient exhibited an AUC value right in the target range, with no dose correction needed, what were the odds for them to stay in
this safe range in the long term? For that, we studied the distribution of the AUC values on visit when the AUC value on visit 0-12h n 1 + 0-12h 
was in the 40 50 h.mg/L interval. Patients with the following criteria were considered: multiple AUC measurements beyond the firstn –
year after transplantation, no modification of MMF dose and same associated CNI over the follow-up.
In patients in whom the MMF dose had been doubled between 2 AUC measurements, was the AUC value doubled? For that, we
studied the distribution of the individual ratios between AUC on visit n 1 and AUC on visit n. Patients with the following criteria were+
considered: (i) multiple AUC measurements beyond the first year after transplantation; (ii) AUC value less than 20 mg.h/L on visit ; (iii)n 
same associated CNI on visit n 1; and (iv) MMF dose on visit double that on visit .+ n 1 + n 
In patients in whom the MMF dose had been divided by 2 between 2 AUC measurements, was the AUC value decreased by half? For
that, we also studied the distribution of the same n 1/n AUC ratio. Patients with the following criteria were considered: (i) multiple AUC+
measurements beyond the first year after transplantation; (ii) AUC value greater than 90 mg.h/L on visit (iii) same associated CNI onn; 
visit and (iv) MMF dose on visit half of that on visit n.n 1; + n 1 +
Results
A total number of 13930 requests, posted on the website from 2005 to 2010, for MMF dose adjustment in renal transplant patients
were analysed. This corresponded to a total number of 7090 different patients monitored in 53 different transplantation centres. Among
these centres, 37 sent more than 10 requests (of which 33 were French). The repartition of these requests as a function of the CNI
combined with MMF and the time elapsed since transplantation is presented in . About a third (4396/13930) of the requeststable 1 
corresponded to the first 3 months post-transplantation. Over this 5-year period, a quite similar number of requests concerned the
MMF-CSA and MMF-TAC drug combinations. However, the proportion of patients given MMF-TAC has progressively increased: 26  in%
2005, 46  in 2006, 55  in 2007, 57  in 2008, 58  in 2009 and 60  in 2010.% % % % %
Depending on the associated CNI and the time elapsed since transplantation, what are the MMF doses prescribed to renal
transplant patients, before any dose adjustment?
Only the first request for each patient was considered, i.e. before any Bayesian dose adjustment performed on the website, resulting in
the selection of 7090 AUC values. Approximately 45  (n 3125) of the AUC values were obtained beyond the first year after% =
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transplantation, about 40  (n 2842) in the first 3 months and 26  (n 1865) in the first month. Whatever the post-transplantation period,% = % =
the mean daily dose of MMF given to these patients was higher when associated with CSA than with TAC (overall, 1898 mg/day vs. 1586
mg/day; p<0.0001) ( and ). In the first month, the mean daily dose of MMF was 2500mg for patients with CSA versusfigure 1 table 2 
1994mg for patients with TAC, and then in both groups it decreased progressively to reach 1600mg and 1200 mg beyond the 1 yearst 
post-transplantation.
More precisely, in the first month, 56  of the patients with CSA received 3g/day of MMF and 38  of them 2g/day, whereas these% %
proportions were of 28  and 49  in the following two months. Finally, at the end of the first year, 50  of the patients were given 2g/day.% % %
In patients given MMF-TAC, 73  received 2g/day of MMF in the 1 month versus 17  at the end of the 1 year, when 56  were given% st % st %
1g/day.
What percentage of patients actually needed MMF dose adjustment to reach the 30 60 mg.h/L range?–
For this study, 13930 requests were considered. The results of this study are presented in details in . Considering all thetable 3 
post-transplantation periods and associated CNIs, 35  of the patients were outside the 30 60 AUC range. Interestingly, 25  could be% – %
considered underexposed, the highest proportion being observed during the first month for patients given MMF-CSA.
In the 1 month, for patients given MMF-CSA, the percentage of AUC values in the 30 60 mg.h/L range was significantly higherst –
when the daily dose was 3g/day than 2g/day (72.3  vs. 47.1 ; p<0.001).% %
In the same period, for patients given MMF-TAC, the proportion of AUC values in the recommended range was significantly higher
when the daily dose was 2g/day than <2g/day (69.3  vs. 44.6 ; p<0.001).% %
From the 3 month to the end of the 1 year, 54  of the patients receiving 3g/day MMF in association with CSA had an AUC valuerd st % ≥
in the recommended range and 40  had an AUC > 60 mg.h/L. In the same period, 74.2  of the AUC values were in the recommended% %
range when patients were given 2g/day MMF.
In patients given MMF-TAC between month 3 and year 1, 66  had an AUC value in the recommended range (but about 25  were% %
below 30 mg.h/L) if they were given less than 1g/day, while 32  of those given 1g/day exhibited an AUC > 60 mg.h/L.%
Beyond the 1 year post transplantation, 5.5  (213 out of 3797) of the requests corresponded to patients given MMF-CSA who stillst %
received a daily MMF dose of 3g or more, leading to only 4.7  of AUCs > 60 mg.h/L. Similarly, 16.7  of the requests corresponded to% %
patients given MMF-TAC who still received 2g/day MMF, leading to AUC > 60 mg.h/L in 16  of these patients.≥ %
What is the efficacy of MMF dose adjustment based on Bayesian AUC estimation?
To evaluate the efficiency of Bayesian dose adjustment, we analyzed the data obtained from 3311 renal transplant patients for whom
we received at least 2 AUC requests. As far as we could tell from the comparison of the dose proposed in the previous result and the dose
reported on the next request form, 65 to 78  of the proposed dose adjustments were actually applied by the clinicians, considering all%
post-transplantation periods and spaces of time between 2 dose adjustments. In such cases, 72 to 80  of the estimated AUC values were%
within the 30 60 mg.h/L range. In contrast, when the dose recommendation had not been or was no longer applied, 39 to 57  of the– %
patients were in the target range when the next request was sent. These results are illustrated on .figure 2 
The interindividual AUC variability in the respected-dose  group was systematically lower than that in the not respected-dose  group“ ” “ ”
(depending on the post-transplantation periods, CV   31 to 41  versus 49 to 70 , respectively). As a comparison, the CVs of the AUC% = % %
values corresponding to a first request on the website ranged from 44 to 64 .%
In the 3331 patients, we then studied the effect of time between a dose adjustment proposal and the next AUC measured, at different
post-transplantation periods. When considering patients in the first month after transplantation, the percentage of AUCs in the
recommended range was significantly higher in the respected-dose  group than in the not respected-dose  group when the time elapsed“ ” “ ”
between the 2 visits was less than 2 weeks (79.5 vs 53.7 ; p<0.05), but not when it was more than 2 weeks (70.4 and 55.5 , respectively).% %
Similarly, between the first and the third months post-transplantation, the percentage of respected-dose  AUCs in the recommended range“ ”
tended to be higher when the time elapsed between two dose adjustments was less vs. more than 4 weeks (78.3  vs. 72.6 ; ns). When% %
considering dose-adjustments proposed at different post-transplantation periods between month-3 and year-1, the percentage of subsequent
AUCs in the target range was systematically and significantly higher in the respected-dose  group (p<0.001), whatever the time elapsed“ ”
between the recommendation and the next AUC (although a tendency towards better results was still observed for the shortest periods of
time). For dose recommendations made after one year post-transplantation, patients in the respected-dose  group were also more likely to“ ”
be in the target than those of the not respected-dose  group (p<0.001), the risk of being outside the therapeutic range remaining stable (i.e.“ ”
around 25 ) when the space of time between dose recommendation and the subsequent AUC was more than 3 months.%
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What is the extent of AUC intra-individual variability, and is the dose-exposure relationship linear in the stable period?
In patients beyond the first year after transplantation with no modification in MMF dose and associated CNI between two visits, we
studied the distribution of AUC values on visit when the AUC on visit was within a 40 50 interval. When the time elapsed betweenn 1 + n –
2 AUCs measurements was less than 3 months, 77  of the patients were still in a 30 60 range on visit (i.e. 77/102). This proportion% – n 1 +
was not significantly different when increasing the time-intervals between 2 dose adjustments: 81  (56/69) and 71  (i.e. 110/155) for% %
time intervals < 6 months and < 1 year, respectively. Additionally, no difference was observed when stratifying by associated CNI or
MMF dose ranges. Globally, when the time elapsed between 2 visits was less than one year, the odds to be still in the 30 60 range on the–
following visit was 75.0 .%
The distribution of AUC values observed on visit when the dose was doubled as compared to that of visit is presented in n 1 + n figure
. The AUC /AUC ratio was 1.99  0.81 in patients given MMF-TAC (n 52), but it was significantly lower in patients given3(a) n 1 + n ± =
MMF-CSA (n 60): 1.55  0.74 (p 0.003).= ± =
The distribution of the AUC values observed on visit when the dose was decreased by half is illustrated in . In patientsn 1 + figure 3(b) 
given MMF-TAC, the AUC /AUC ratio was 0.69  0.41. This ratio was 0.80  0.41 in patients given MMF-CSA (n 55) (ns).n 1 + n ± ± =
Discussion
Although the clinical benefit of MMF monitoring is still debated, partly because the clinical evidence is inconsistent and partly
because the best monitoring strategy has still not been agreed upon ( ), we report herein large-scale experience with MMF dose1 
adjustment based on MPA inter-dose AUC. The rationale behind this approach is based on the results of pharmacokinetic and comparative,
randomized trials and on conclusions of expert consensus conferences, which stated that the inter-dose AUC best reflects the exposure to
MPA and that a target range of 30 to 60 mg.h/L for AUC (respectively 20 to 40 mg.h/L for AUC when MMF is given t.i.d.)0-12h 0-8h 
probably corresponds to an acceptable, if not the best, efficacy/toxicity compromise for different contexts in transplantation.
Within a 5-year period, transplantation centres have been using the expert system proposed on the ISBA website and have sent a very
large number of requests for routine dose adjustment of MMF in different transplantation conditions, which gives an insight into the actual
use of MMF monitoring. This has allowed the setting-up of a very large database of routine MPA PK profiles, all estimated using the same
PK tools, that we partially analyzed herein. In the present study, only the requests where the MPA measurements were performed using
either an HPLC technique (with either ultraviolet or mass-spectrometric detection) or the enzyme inhibition assay were considered.
Additionally, an enzyme inhibition assay has emerged. Due to its higher sensitivity and specificity, HPLC-MS is often described as the
gold standard technique ( ). The enzyme inhibition assay does not seem to be significantly affected by metabolite interference as22 
different studies have reported a good agreement with results from chromatographic assays when measuring MPA concentrations in
transplant patients receiving MMF ( , , ). In the report of the last consensus meeting on TDM of MPA ( ), a summary of method16 23 24 1 
performance for the measurement of MPA was performed. This study reported that the EMIT assay can lead to an overestimation by
approximately 25  due to its cross-reactivity with metabolites of MPA, and exhibits an imprecision of 6 to 8  at a concentration of% %
1mg/L.
Considering about 7000 kidney transplant patients followed in multiple transplantation centres (most of them being French), the
number of requests concerning the MMF-TAC and the MMF-CSA associations was quite similar. However, the proportion of patients with
TAC has progressively increased over this period and almost 2/3 of the requests posted in the past months have concerned the MMF-TAC
association.
We observed that the mean daily dose of MMF prescribed in the first month after transplantation to patients given MMF-CSA was
approximately 2.5g, whereas that of patients given MMF-TAC was close to 2g. These daily doses slightly decrease over
post-transplantation time to reach, in the long term, about 1.6g and 1.2g, respectively. The SPC of Cellcept  recommends a dose of 1g®
twice daily in renal transplant patients. However, greater than 10-fold ranges in MPA-AUC have been observed in different populations of
transplanted patients receiving this standard dose ( , , ). MPA pharmacokinetics is affected by the nature of the associated1 10 13 
immunosuppressive and evolves with post-transplantation time, MPA-AUC being approximately 30 50  lower in the early– %
post-transplantation period than three months after transplantation, for the same dose (this being sometimes called AUC pharmacokinetics“
maturation ). For these reasons, the recommendations made after a roundtable meeting were to start with an MMF dose of 1.5g bid,”
especially for patients on concurrent CSA ( ). In the present study, no more than half of the AUC values were in the 30 60 range for7 –
patients given MMF 2g/day in the first weeks after transplantation, whereas about 3/4 reached this range with 3g/day. However, one
should not consider 3g/day as a gold standard dose as, for this period, a non negligible percentage of patients needed more than 3g/day or
less than 2g. In a study based on the data of the FDCC trial, van Gelder found a significant relationship between MPA-AUC on day 3 and
the incidence of biopsy-proven acute rejection (BPAR) in the first month (p 0.009) or in the first year posttransplantation (p 0.006) ( ).= = 12 
This study also reported that the risk of developing BPAR during the first year was significantly lower in patients with a day-3 AUC > 30
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mg.h/L ( ). In the APOMYGRE trial ( ) where 137 renal allograft recipients were randomized to receive either12 13 
concentration-controlled doses or a fixed dose of MMF, 7 out of the 10 episodes of BPAR that occurred in the first 3 months
post-transplantation were associated with an MPA AUC value 30 mg.h/L, three with a value between 30 and 45 mg.h/L, and none with< 
an AUC 45 mg.h/L. For these reasons, an AUC of 45 mg.h/L may be considered as the best single target in patients on cyclosporine and> 
was recently substituted for the 30 60 h.mg/L range as the dose-adjustment criterion on the ISBA website. When retrospectively–
considering this single target of 45 mg.h/L in the present study, we calculated that in the first 3 months post-transplantation, 82.7  (1294%
out of 1565) of the na ve  patients receiving MMF-CSA and 64.9  (1837out of 2831) of those given MMF-TAC were underexposed. This‘ ï ’ %
suggests that in CNI withdrawal protocols, patients should be also monitored carefully for MPA exposure to minimize the incidence of
acute rejection.
Considering all post-transplant periods and drug combinations, more than 75  of the patients reached the target AUC range at their%
second visit when they were (still) receiving the dose proposed as a result of a previous dose adjustment on ISBA. When a dose adjustment
had been proposed, the subsequent AUC was significantly more often in this recommended range if the dose was (still) applied than not, at
all post-transplantation periods (72 80  vs. 43 54 ).– % – %
When the first dose adjustment was performed in the first two weeks post-transplantation the odds to be (still) in the target range was
maximal (i.e., more than 80 ) for the following two weeks, but less (even if still better than no dose adjustment) thereafter. This result is%
in accordance with the systematic increase in MMF exposure in this period and with recommendations that TDM should be performed on
days 3, 7 and once between days 10 to 14 post-transplantation ( ). For later post-transplantation periods, the percentage of patients in the7 
target was systematically and significantly higher if they received a dose within the previously proposed dose range than not, whatever the
time interval between two AUC measurements.
In this study, we proposed to answer to two frequent clinical situations: a patient is in the stable phase (usually beyond the first year
post-transplantation) and has either a low or a high AUC value requiring either to double or to halve the dose. In such case, what are the
odds to either double or halve the exposure? We found that when the dose was doubled, the next AUC value was doubled on average in
patients given MMF-TAC, however with a large interpatient variability, while it was only multiplied by 1.6 in patients given MMF-CSA.
The well-known interaction between CSA and MPA could at least explain these results. On the contrary, when the dose had been divided
by 2, the exposure was reduced by 30 40 , without a significant difference between the 2 groups of patients. Thus, from our database, we– %
determined that for patients in the stable post-transplantation period given 2g/day MMF, the mean AUC was 48  14 mg.h/L in the ± “
MMF-TAC  group (n  497) versus 37  16 mg.h/L in the MMF-CSA  group (n  1614). For a daily dose of 1g, these AUC values were” = ± “ ” =
31  15 (n  1362) and 30 14 mg.h/L (n  865), respectively. This suggests that the interaction with CSA might be negligible for the± = ± =
smallest doses of MMF and more pronounced when MMF doses increase. There are several studies reporting a lower exposure to MPA in
patients receiving MMF in combination with CSA than in those receiving MMF and TAC or sirolimus or MMF alone ( ). Thus, in25 –28 
contrast to TAC, CSA is an inhibitor of OATP1B3 and MPRP2, two transporters involved in the biliary excretion of MPA-phenyl
glucuronide, and so decreases the enterohepatic cycling of MPA through inhibition of MPA-phenyl glucuronide excretion into the bile (29 
). This phenomenon can be schematized as follows: (i) in the presence of CSA, there is a decrease in the number of transporters available
for 7-0-MPA- -glucuronide (MPAG). When the dose of MMF is low, this decrease has very little impact because the number of availableβ
receptors is not a limiting factor; (ii) For higher doses of MMF, saturation of the remaining transporters is observed and a higher
proportion of MPAG accumulates in the body. Neither the CSA dose nor any trough or C2 concentration was available for this study.
However, in a population of 207 kidney recipients in the stable phase, Etienne et al. compared the exposure to MPA between patients
receiving CSA dose-adjusted to reach an AUC0-12h of either 4.3 or 2.2 g.h/L (corresponding to average doses of 2.1 mg/kg/day and 3.1μ
mg/kg/day, which again shows the non-linearity of the dose-exposure relationship). These authors reported that this decrease in CSA
exposure/dose led to a 14  increase in the exposure to MPA.%
The main objective of the ISBA website is to help clinicians individualize the dose of immunosuppressive drugs on the basis of their
inter-dose AUC. For MMF, results are typically reported with a dose range to reach an AUC in the 30 60 mg.h/L range, together with a–
personalized comment if the context of the request has been filled in. However, without information on the patient s clinical status, risk of’
rejection, co-morbidity, side-effects or CNI levels, the proposed dose increases or decreases are suggestions to be appraised globally by the
clinician together with the clinical findings. As the final decision always lies with the physician, it might partially explain why
approximately one third of the propositions were not followed. However, two thirds were applied and apparently led to approximately 80%
patients in the target range, with a decrease in the number of patients with over- or under-exposure. Since February 2008, when filling in
the form for dose adjustment, the clinicians are invited to give information about the context of their request. An analysis of 3418 requests
posted during 2010 showed that 64  were posted for systematic TDM, 33  for checking a previous dose adjustment, 2  for side-effects,% % %
1  for a suspicion of acute or chronic rejection.%
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In conclusion, this retrospective analysis of more than 13000 PK profiles obtained from renal transplant patients given MMF, if not
able to evaluate the clinical benefit of such a TDM strategy, showed the efficacy of MMF TDM based on AUC measurements in reducing
the variability of MPA exposure, early after transplantation as well as in the long term, and in minimizing the frequency of patent under- or
over-exposure.
Optimizing MMF TDM does not require a high frequency of AUC measurement to maintain the patients in the target. Actually, if in
the early period it was observed that checking the AUC every two to six weeks maximized the chance to maintain the AUC in the target, in
the stable phase, when the intra-individual variability is reduced, dose adjustment every 6 months up to one year was not detrimental. In
our opinion, MMF TDM should probably also be performed when the associated immunosuppressant regimen is substantially modified
(which was not be studied here apart from the difference between CSA and TAC), or in case of rejection or adverse events. In any case,
this study based on a very large number of requests received from many centres show that, despite the inconvenience of drawing blood
samples three times within the first 3h post-dose, this approach is clinically feasible, and apparently acceptable by the patients, the nurses
and the physicians.
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Figure 1
Distribution of the daily doses of MMF given to kidney transplant patients at different post-transplantation periods (M: month), sorted by
combined calcineurin inhibitor.
Figure 2
Distribution of the MPA AUC values at different post-transplantation periods (M: month) in patients who had benefited from consecutive
AUC measurements. (The line in the box is the median. The lower edge of the box represents the 10th percentile and the upper edge the 90th
percentile).
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Figure 3
Distribution of MPA AUC values observed on visit when the dose was doubled as compared to that of visit and when the dose wasn 1 + n (a) 
decreased by half as expressed by the AUC /AUC ratios. (The line in the box is the median. The lower edge of the box represents the 10thn 1 + n 
percentile and the upper edge the 90th percentile).
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Table 1
Summary of the requests sent for the routine dose adjustment of mycophenolate mofetil in adult renal transplant patients, at different post-transplantation periods.
Type of graft Kidney
Combined CNI CSA TAC
Post-transplantation period (days)
< 30 890 1363
30 90– 675 1468
90 365– 1337 1850
> 365 3636 2711
Total 6538 7392
Number of transplantation centres involved n 46= n 51=
CNI: calcineurin inhibitor; CSA: cyclosporine A; TAC: tacrolimus
Table 2
Mean daily doses of MMF prescribed to kidney transplant patients, sorted by post-transplantation period and combined calcineurin inhibitor (CNI).
MMF daily dose (mg)
Combined CNI
Post-transplantation period (months) CSA TAC p
< 1 2558  556± 1994  502± < 0.0001
1  3– 2192  736± 1742  512± < 0.0001
3  12– 1832  626± 1420  544± < 0.0001
> 12 1624  556± 1216  500± < 0.0001
Overall 1898  694± 1586  606± < 0.0001
Results are expressed as mean  standard deviation. CSA: cyclosporine A; TAC: tacrolimus±
Table 3
Distribution of the MPA AUC values.
Post-transplantation period
< W2
Combined CNI CSA TAC
MMF morning dose < 1000 * 1000 1500 <1000 1000 >1000
AUC < 30 49.1 53.7* 26.2* 51* 25.3* 15.0*
30 < AUC < 60 43.4 45.7 71.3 43.3 68.5 60.0
AUC > 60 7.5 0.5 2.4 5.8 6.2 25.0
W2  M1–
Combined CNI CSA TAC
MMF morning dose < 1000 1000 1500 > 1500 <1000 1000 >1000
AUC < 30 50.9 48.2 22.2 19.0 51.4 14.7 12.0
30 < AUC < 60 45.5 51.1 73.7 76.2 45.7 70.8 68.0
AUC > 60 3.6 0.7 4.2 4.8 2.9 14.5 20.0
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M1  M3–
Combined CNI CSA TAC
MMF morning dose < 1000 1000 1500 > 1500 <1000 1000 >1000
AUC < 30 32.4 26.6 6.1 8.7 30.7 9.4 2.9
30 < AUC < 60 62.3 69.2 52.9 73.9 63.1 60.3 59.2
AUC > 60 5.3 4.3 41.0 17.4 6.3 30.3 37.9
M3  M6–
Combined CNI CSA TAC
MMF morning dose < 1000 1000
 1500≥ <1000 1000
AUC < 30 29.6 21.5 11.0 28.3 16.7
30 < AUC < 60 62.3 74.2 78.0 65.7 52.6
AUC > 60 8.1 4.3 11.0 5.9 30.7
M6  M12–
Combined CNI CSA TAC
MMF morning dose < 1000 1000
 1500≥ <1000 1000
AUC < 30 28.3 17.6 2.4 27.7 28.1
30 < AUC < 60 62.4 75.3 33.3 66.1 36.0
AUC > 60 6.1 7.1 64.3 6.2 36.0
> M12
Combined CNI CSA TAC
MMF morning dose < 1000 1000
 1500≥ <1000 1000
AUC < 30 31.6 17.6 16.0 25.5 15.6
30 < AUC < 60 62.3 76.9 76.3 68.4 67.8
AUC > 60 6.1 5.6 7.7 6.0 16.6
 * Results are expressed as percentage of evaluated renal transplant patients. CSA: cyclosporine A; TAC: tacrolimus; W: week; M: month; AUC is expressed as mg h/l; Dose is given in mg.·
